Sugi Predict

Sugi Predict / Compounds / SCHEMBL192054

SCHEMBL192054

SCHEMBL192054

COC(=O)NC(C(=O)O)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.40
▸ CA1 P00915 1/20 0.32
▸ CA7 P43166 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TGFBR1 P36897 1/20 0.31
▸ CTSS P25774 1/20 0.31
▸ CTSK P43235 1/20 0.31
▸ ADAM17 P78536 1/20 0.30
▸ PYGL P06737 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14479851 1.00 CA2 (0.40) CA2CA1CA7CNR2MEN1
SCHEMBL6418 1.00 CA2 (0.40) CA2CA1CA7CNR2MEN1
SCHEMBL193767 0.84 MEN1 (0.31) MEN1GAAKMT2ATGFBR1
SCHEMBL193766 0.84 MEN1 (0.31) MEN1GAAKMT2ATGFBR1
SCHEMBL204757 0.83 MEN1 (0.33) MEN1GAAKMT2A
SCHEMBL15898007 0.83 GAA (0.33) MEN1GAAKMT2A
SCHEMBL1985522 0.83 MEN1 (0.33) MEN1GAAKMT2A
SCHEMBL90052 0.83 CA2 (0.50) CA2CA1CA7MEN1GAA
SCHEMBL57432 0.83 CA2 (0.50) CA2CA1CA7MEN1GAA
SCHEMBL83699 0.83 CA2 (0.50) CA2CA1CA7MEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP claimed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US claimed
EP-4649086-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION Merck Sharp & Dohme LLC (US) 2025-11-19 — — EP disclosed
US-12441762-B2 Hepatitis c virus NS3/4A protease inhibitors UNIVERSITY OF MASSACHUSETTS (US) 2025-10-14 — — US disclosed
US-20250223259-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION MERCK SHARP & DOHME LLC (US) 2025-07-10 — — US disclosed
US-20250051246-A1 Deuterated Antiviral Compounds PFIZER INC. (US) 2025-02-13 — — US disclosed
EP-4460508-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION Merck Sharp & Dohme LLC (US) 2024-11-13 — — EP disclosed
WO-2024151465-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION MERCK SHARP & DOHME LLC (US) 2024-07-18 — — WO disclosed
US-20240150318-A1 PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS THE SCRIPPS RESEARCH INSTITUTE 2024-05-09 — — US disclosed
EP-4352040-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS The Scripps Research Institute (US) 2024-04-17 — — EP disclosed
CN-117794896-A Protease inhibitors for the treatment of coronavirus infections 斯克里普斯研究学院 2024-03-29 — — CN disclosed
WO-2006086381-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 — — WO disclosed
EP-1687018-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2006-08-09 — — EP disclosed
US-20060172950-A1 Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid WANG XIANGDONG A 2006-08-03 — — US disclosed
US-6995174-B2 for inhibiting proteases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-07 — — US disclosed
US-20050187165-A1 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-08-25 — — US disclosed
WO-2005046712-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-26 — — WO disclosed
EP-1505963-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 — — EP disclosed
US-20040106559-A1 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-03 — — US disclosed
WO-2003099274-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051246-A1 Deuterated Antiviral Compounds SARS1, ACE2, CCND3 CA2 1869/4885CA1 2905/4885CA7 3451/4885
US-12441762-B2 Hepatitis c virus NS3/4A protease inhibitors HAVCR2, CTSC, DPP4 CA2 4694/4885CA1 4693/4885CA7 4156/4885
US-20050187165-A1 Hepatitis C virus inhibitors HAVCR2, HCCS, RRP1B CA2 4580/4885CA1 4622/4885CA7 3554/4885
US-20250223259-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION ACE2, PRSS2, PRSS1 CA2 743/4885CA1 1503/4885CA7 2076/4885
US-20040106559-A1 Hepatitis C virus inhibitors HAVCR2, HCCS, RNASE1 CA2 4434/4885CA1 4222/4885CA7 3501/4885
US-20240150318-A1 PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS ACE, ACE2, TMPRSS2 CA2 1809/4885CA1 4006/4885CA7 2828/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA2 4674/4885CA1 4852/4885CA7 4349/4885
US-20060172950-A1 Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid PRSS1, CTRL, CTRB1 CA2 2491/4885CA1 1483/4885CA7 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.